मिथाइलीन ब्लू के इंटरैक्शन

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

Avoid concomitant use of PROVAYBLUE with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs) and opioids. [see Warnings and Precautions ( 5.1 ) and Drug Interactions ( 7.1 )]. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

CONTRAINDICATIONS IOPIDINE 1% Ophthalmic Solution is contraindicated for patients receiving monoamine oxidase inhibitor therapy and for patients with hypersensitivity to any component of this medication or to clonidine. (एप्राक्लोनिडिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [ see Warnings and Precautions (5.7) , Drug Interactions (7.1) ]. (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (एम्फेटामाइन और डेक्सट्रोएम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (मिथाइलीन ब्लू लेबल, दवाओं के इंटरैक्शन)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

Concomitant use of monoamine oxidase inhibitors (MAOIs). (कार्बामाज़ेपिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Nonselective monoamine oxidase (MAO) inhibitors are contraindicated for use with levodopa or carbidopa-levodopa combination products with or without carbidopa. (कार्बिडोपा लेबल, निषेध (कॉन्ट्राइंडिकेशन))

DUOPA is contraindicated in patients who are currently taking a nonselective monoamine oxidase (MAO) inhibitor (e.g., phenelzine and tranylcypromine) or have recently (within 2 weeks) taken a nonselective MAO inhibitor. (कार्बिडोपा और लेवोडोपा लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Carbidopa, levodopa and entacapone tablets is contraindicated in patients: Taking nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine). (कार्बिडोपा, लेवोडोपा और एंटाकैपोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…because deaths have been reported in this age group [see Warnings and Precautions (5.1)]. patients who are hypersensitive to carbinoxamine maleate or any of the inactive ingredients in Carbinoxamine Maleate Extended-Release Oral Suspension [see Warnings and Precautions (5.4)]. patients who are taking monoamine oxidase inhibitors (MAOI) [see Drug Interactions (7)]. (कार्बिनोक्सामिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (मिथाइलीन ब्लू लेबल, दवाओं के इंटरैक्शन)

• Concomitant use of monoamine oxidase inhibitors (MAOIs), or use within 14 days of stopping MAOIs. (ज़िप्रासिडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

• Taking monoamine oxidase inhibitors (MAOIs). (टेट्राबेनाज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (मिथाइलीन ब्लू लेबल, दवाओं के इंटरैक्शन)

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (मिथाइलीन ब्लू लेबल, दवाओं के इंटरैक्शन)

During or within 14 days following the administration of monoamine oxidase inhibitors, hypertensive crises may result. (डाइएथिलप्रोपियॉन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Avoid use of diphenoxylate hydrochloride and atropine sulfate in patients who take MAOIs and monitor for signs and symptoms of hypertensive crisis (headache, hyperthermia, hypertension). (डाइफेनोक्सिलेट और एट्रोपिन लेबल, दवाओं के इंटरैक्शन)

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (मिथाइलीन ब्लू लेबल, दवाओं के इंटरैक्शन)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

Antihistamines are also contraindicated in the following conditions: Hypersensitivity to dexchlorpheniramine maleate or other antihistamines of similar chemical structure Monoamine oxidase inhibitor therapy (See Drug Interaction section) (डेक्सक्लोरफेनिरामिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Drug Interactions ]. (डेक्सट्रोएम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Opioids and dextromethorphan may increase the risk of developing serotonin syndrome. (मिथाइलीन ब्लू लेबल, चेतावनियां और सावधानियां)

Opioids and dextromethorphan may increase the risk of developing serotonin syndrome. (मिथाइलीन ब्लू लेबल, चेतावनियां और सावधानियां)

• Concomitant treatment with monoamine oxidase inhibitors (MAOIs) or within 14 days following discontinuation of treatment with an MAOI, because of the risk of hypertensive crises [see Drug Interactions ( 7.1 )] . (डेक्समिथाइलफेनिडेट लेबल, निषेध (कॉन्ट्राइंडिकेशन))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

…Known hypersensitivity to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any inactive ingredient in the formulation Monoamine oxidase (MAO) inhibitors intensify and prolong the adverse central nervous system effects of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets [ see Drug Interactions… (डॉक्सीलामिन और पाइरिडोक्सिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

Taking monoamine oxidase inhibitors (MAOIs). (ड्यूटेट्राबेनाज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

However, based on mechanism of action, the use of non-selective MAO inhibitors and linezolid should be avoided as there is a potential for increased blood pressure when taken with NORTHERA. (ड्रॉक्सीडोपा लेबल, दवाओं के इंटरैक्शन)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

Avoid concomitant use of PROVAYBLUE with medicinal products that enhance serotonergic transmission including antidepressants like SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin and norepinephrine reuptake inhibitors), MAOIs (monoamine oxidase inhibitors), bupropion, buspirone, clomipramine, mirtazapine, linezolid, opioids, and dextromethorphan… (मिथाइलीन ब्लू लेबल, दवाओं के इंटरैक्शन)

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (मिथाइलीन ब्लू लेबल, दवाओं के इंटरैक्शन)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (मिथाइलीन ब्लू लेबल, दवाओं के इंटरैक्शन)

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (मिथाइलीन ब्लू लेबल, दवाओं के इंटरैक्शन)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

Opioids and dextromethorphan may increase the risk of developing serotonin syndrome. (मिथाइलीन ब्लू लेबल, चेतावनियां और सावधानियां)

…cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] With glaucoma [see Warnings and Precautions (5.3) ] With hyperthyroidism Taking or within 14 days of stopping a monoamine oxidase inhibitors [see Drug Interactions (7) ] With known hypersensitivity to phentermine, topiramate or any of the excipients in phentermine and topiramate extended-release… (फेंटरमिन और टोपिरामेट लेबल, निषेध (कॉन्ट्राइंडिकेशन))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

…coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension, pulmonary hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy (see PRECAUTIONS, Pregnancy ) • Nursing • Use in combination with other… (फेनडाइमेट्राज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (मिथाइलीन ब्लू लेबल, दवाओं के इंटरैक्शन)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (मिथाइलीन ब्लू लेबल, दवाओं के इंटरैक्शन)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

…including antidepressants like SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin and norepinephrine reuptake inhibitors), MAOIs (monoamine oxidase inhibitors), bupropion, buspirone, clomipramine, mirtazapine, linezolid, opioids, and dextromethorphan because of the potential for serious CNS reactions, including potentially fatal serotonin syndrome. (मिथाइलीन ब्लू लेबल, दवाओं के इंटरैक्शन)

Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly or within 14 days following use of monoamine oxidase inhibitors. (बेंज़फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

Avoid concomitant use of PROVAYBLUE with medicinal products that enhance serotonergic transmission including antidepressants like SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin and norepinephrine reuptake inhibitors), MAOIs (monoamine oxidase inhibitors), bupropion, buspirone, clomipramine, mirtazapine, linezolid, opioids, and dextromethorphan… (मिथाइलीन ब्लू लेबल, दवाओं के इंटरैक्शन)

Opioids and dextromethorphan may increase the risk of developing serotonin syndrome. (मिथाइलीन ब्लू लेबल, चेतावनियां और सावधानियां)

Avoid use of MAO inhibitors or linezolid with midodrine. (मिडोड्रिन लेबल, दवाओं के इंटरैक्शन)

CONTRAINDICATIONS Methyldopa is contraindicated in patients: – with active hepatic disease, such as acute hepatitis and active cirrhosis. – with liver disorders previously associated with methyldopa therapy (see WARNINGS ). – with hypersensitivity to any component of this product. – on therapy with monoamine oxidase (MAO) inhibitors. (मिथाइलडोपा लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Concomitant treatment with monoamine oxidase inhibitors (MAOIs), and also within a minimum of 14 days following discontinuation of treatment with a monoamine oxidase inhibitor because of the risk of hypertensive crisis [see Drug Interactions (7.1) ]. (मिथाइलफेनिडेट लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (मिथाइलीन ब्लू लेबल, दवाओं के इंटरैक्शन)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (मेटाक्सालोन लेबल, दवाओं के इंटरैक्शन)

In one study in hypertensive patients, intravenously administered metoclopramide was shown to release catecholamines; hence, avoid use in patients with hypertension or in patients taking monoamine oxidase inhibitors [see Drug Interactions ( 7.1 )] . (मेटोक्लोप्रामाइड लेबल, चेतावनियां और सावधानियां)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (मेथएम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (मिथाइलीन ब्लू लेबल, दवाओं के इंटरैक्शन)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (मिथाइलीन ब्लू लेबल, दवाओं के इंटरैक्शन)

…including antidepressants like SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin and norepinephrine reuptake inhibitors), MAOIs (monoamine oxidase inhibitors), bupropion, buspirone, clomipramine, mirtazapine, linezolid, opioids, and dextromethorphan because of the potential for serious CNS reactions, including potentially fatal serotonin syndrome. (मिथाइलीन ब्लू लेबल, दवाओं के इंटरैक्शन)

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Precautions (5.7) and Drug Interactions (7.1) ] . (लिसडेक्सएम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

INBRIJA is contraindicated in patients currently taking a nonselective monoamine oxidase (MAO) inhibitor (e.g., phenelzine and tranylcypromine) or who have recently (within 2 weeks) taken a nonselective MAO inhibitor. (लेवोडोपा लेबल, निषेध (कॉन्ट्राइंडिकेशन))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

Dose adjustments due to drug interactions ( 2.4 , 7.1 ): Factors Dose Adjustments for INGREZZA and INGREZZA SPRINKLE Use of MAOIs with INGREZZA or INGREZZA SPRINKLE Avoid concomitant use with MAOIs. (वाल्बेनाज़िन लेबल, दवाओं के इंटरैक्शन)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

Avoid concomitant use of PROVAYBLUE with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs) and opioids. [see Warnings and Precautions ( 5.1 ) and Drug Interactions ( 7.1 )]. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (मिथाइलीन ब्लू लेबल, दवाओं के इंटरैक्शन)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (मिथाइलीन ब्लू लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitor therapy (See DRUG INTERACTIONS ). (साइप्रोहेप्टाडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

सेंट जॉन्स वॉर्ट को एंटीडिप्रेसेंट और अन्य सेरोटोनर्जिक दवाओं के साथ लेने से सेरोटोनिन सिंड्रोम का जोखिम बढ़ता है। (NCCIH, St. John's Wort)

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (मिथाइलीन ब्लू लेबल, दवाओं के इंटरैक्शन)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

Warnings Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. (स्यूडोएफेड्रिन लेबल, चेतावनियां)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (मिथाइलीन ब्लू लेबल, बॉक्स्ड चेतावनी)

Consider methylene blue for treatment of encephalopathy. (आइफॉस्फामाइड लेबल, चेतावनियां और सावधानियां)

Drugs that may potentiate clinical response of Isoproterenol Clinical Impact The effects of isoproterenol may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine. (आइसोप्रेनालिन लेबल, दवाओं के इंटरैक्शन)

Concomitant Use with MAO Inhibitors Concomitant use of MAO inhibitors and inhalational anesthetics may increase the risk of hemodynamic instability during surgery or medical procedures. (आइसोफ्लुरेन लेबल, दवाओं के इंटरैक्शन)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (आरफॉर्मोटेरोल लेबल, दवाओं के इंटरैक्शन)

The administration of local anesthetic solutions containing epinephrine to patients receiving monoamine oxidase inhibitors, nonselective beta-adrenergic antagonists, or tricyclic antidepressants may produce severe, prolonged hypertension. (आर्टिकेन और एड्रेनालिन लेबल, दवाओं के इंटरैक्शन)

Monoamine Oxidase (MAO) Inhibitors Caution should be used when concomitantly administering MAO inhibitors and NUVIGIL. (आर्मोडाफिनिल लेबल, दवाओं के इंटरैक्शन)

Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. (इंसुलिन एस्पार्ट लेबल, दवाओं के इंटरैक्शन)

…Glargine-yfgn Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors,… (इंसुलिन ग्लार्जिन लेबल, दवाओं के इंटरैक्शन)

…Degludec Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors,… (इंसुलिन डेग्लुडेक लेबल, दवाओं के इंटरैक्शन)

…with LEVEMIR Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors,… (इंसुलिन डेटेमिर लेबल, दवाओं के इंटरैक्शन)

Clinically Significant Drug Interactions with LYUMJEV Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (इंसुलिन लिस्प्रो लेबल, दवाओं के इंटरैक्शन)

Monoamine Oxidase Inhibitors or Tricyclic Antidepressants Ipratropium Bromide and Albuterol Sulfate Inhalation Solution should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents because the action of albuterol sulfate on the cardiovascular… (इप्राट्रोपियम और सैल्बुटामोल लेबल, दवाओं के इंटरैक्शन)

• Drugs that potentiate the effects of epinephrine include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (एड्रेनालिन लेबल, दवाओं के इंटरैक्शन)

The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression. (एस्टाज़ोलम लेबल, दवाओं के इंटरैक्शन)

Monoamine Oxidase Inhibitors Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines. (ऑक्सीमेटाज़ोलिन लेबल, दवाओं के इंटरैक्शन)

Hypotensive agents (e.g., reserpine, MAO inhibitors, clonidine) may increase the risk of hypotension and/or severe bradycardia. (कार्वेडिलोल लेबल, दवाओं के इंटरैक्शन)

Monoamine-oxidase inhibitors: Concomitant administration may potentiate the effects and toxicity of monoamine-oxidase inhibitors. (कोकेन लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines. (क्लेमास्टिन लेबल, दवाओं के इंटरैक्शन)

…Interactions The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs. (क्लोनाज़ेपाम लेबल, दवाओं के इंटरैक्शन)

The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants. (क्लोराज़ेपेट लेबल, दवाओं के इंटरैक्शन)

Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (क्लोरोप्रोकेन लेबल, सावधानियां)

…increase the susceptibility to and/or intensity of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, nonsteroidal anti-inflammatory… (ग्लिपिज़ाइड लेबल, दवाओं के इंटरैक्शन)

Glipizide: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents, some azoles, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. (ग्लिपिज़ाइड और मेटफॉर्मिन लेबल, सावधानियां)

…Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, ACE inhibitors, disopyramide, fluoxetine, clarithromycin, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents. (ग्लिबेनक्लामाइड लेबल, दवाओं के इंटरैक्शन)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (ग्लिमेपिराइड लेबल, दवाओं के इंटरैक्शन)

Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (टरब्यूटालिन लेबल, सावधानियां)

MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines. (डाइफेनहाइड्रामिन लेबल, दवाओं के इंटरैक्शन)

…drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (डाइसाइक्लोमिन लेबल, दवाओं के इंटरैक्शन)

…be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of Valium, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. (डायज़ेपाम लेबल, दवाओं के इंटरैक्शन)

…1) clinically significant bradycardia (less than 50 bpm), 2) any clinically significant cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval (see PRECAUTIONS, Drug Interactions ), and 6) electrolyte imbalance,… (ड्रोपेरिडोल लेबल, चेतावनियां)

…Nateglinide Drugs That May Increase the Blood-Glucose-Lowering Effect of Nateglinide and Susceptibility to Hypoglycemia Drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g., methandrostenolone), guanethidine, gymnema sylvestre, glucomannan, thioctic acid,… (नेटेग्लिनाइड लेबल, दवाओं के इंटरैक्शन)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (पियोग्लिटाज़ोन और ग्लिमेपिराइड लेबल, दवाओं के इंटरैक्शन)

…Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration of local anesthetic injections containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (प्रिलोकेन और एड्रेनालिन लेबल, दवाओं के इंटरैक्शन)

Monoamine Oxidase Inhibitors (MAOI) Drug interactions, including an increased incidence of extrapyramidal effects, have been reported when some MAOI and phenothiazines are used concomitantly. (प्रोमेथाज़िन लेबल, दवाओं के इंटरैक्शन)

Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (फिनाइलएफ्रिन लेबल, दवाओं के इंटरैक्शन)

• MAO inhibitors, tricyclic antidepressants and drugs that prolong QTc interval may potentiate effect on the cardiovascular system. (फॉर्मोटेरोल लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (फ्लुटिकासोन और सैल्मेटेरोल लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (बुडेसोनाइड और फॉर्मोटेरोल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. (ब्यूटाल्बिटल और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. (ब्यूटाल्बिटल, एस्पिरिन और कैफीन लेबल, दवाओं के इंटरैक्शन)

Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. (ब्यूटाल्बिटल, पैरासिटामोल और कैफीन लेबल, दवाओं के इंटरैक्शन)

…of Adverse Reactions Due to Drug Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors… (ब्यूपिवाकेन लेबल, चेतावनियां और सावधानियां)

…of Adverse Reactions Due to Drug Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors… (ब्यूपिवाकेन और एड्रेनालिन लेबल, चेतावनियां और सावधानियां)

Monoamine oxidase inhibitors may result in increased hypotension. (ब्रिमोनिडिन लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors may result in increased hypotension. (ब्रिमोनिडिन और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Catecholamine depleting drugs (e.g., reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. (मेटोप्रोलोल लेबल, दवाओं के इंटरैक्शन)

Catecholamine-depleting drugs (e.g., MAO inhibitors): Hypotension, bradycardia. (मेटोप्रोलोल और हाइड्रोक्लोरोथायज़ाइड लेबल, दवाओं के इंटरैक्शन)

Likewise, solutions of mepivacaine containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result. (मेपिवाकेन लेबल, चेतावनियां)

Monoamine Oxidase (MAO) Inhibitors Caution should be used when concomitantly administering MAO inhibitors and PROVIGIL. (मोडाफिनिल लेबल, दवाओं के इंटरैक्शन)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (यूमेक्लिडिनियम और विलैंटेरोल लेबल, दवाओं के इंटरैक्शन)

…Significant Drug Interactions with AFREZZA Antidiabetic agents, Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blocking Agents, Disopyramide, Fibrates, Fluoxetine, Monoamine Oxidase Inhibitors, Pentoxifylline, Pramlintide, Salicylates, Somatostatin Analogs (e.g., octreotide), and Sulfonamide Antibiotics Prevention or Management Monitor blood glucose… (रेगुलर इंसुलिन (ह्यूमन) लेबल, दवाओं के इंटरैक्शन)

Clinically Significant Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. (लिडोकेन लेबल, दवाओं के इंटरैक्शन)

Risk of Adverse Reactions Due to Drug Interactions with FLAVALTA Risk of Severe, Persistent Hypertension Due to Drug Interactions Between FLAVALTA and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of FLAVALTA (containing a vasoconstrictor, epinephrine) in patients receiving monoamine oxidase inhibitors (MAOI), or tricyclic antidepressants… (लिडोकेन और एड्रेनालिन लेबल, चेतावनियां और सावधानियां)

Monoamine oxidase inhibitors (MAOs) or tricyclic antidepressants : May potentiate effect of albuterol on the cardiovascular system. (लेवोसैल्बुटामोल लेबल, दवाओं के इंटरैक्शन)

The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (सक्सिनिलकोलिन लेबल, दवाओं के इंटरैक्शन)

Non-selective MAO-inhibitors Concomitant use of MAO inhibitors and inhalational anesthetics may increase the risk of hemodynamic instability during surgery or medical procedures. (सेवोफ्लुरेन लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (सैल्बुटामोल लेबल, दवाओं के इंटरैक्शन)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (सैल्मेटेरोल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions MAO inhibitors should be used with caution in patients receiving hydralazine. (हाइड्रालाज़िन लेबल, दवाओं के इंटरैक्शन)

It is theoretically possible, therefore, that the combination of Entacapone Tablets and a non-selective MAO inhibitor (e.g., phenelzine and tranylcypromine) would result in inhibition of the majority of the pathways responsible for normal catecholamine metabolism. (एंटाकैपोन लेबल, चेतावनियां)

Clonidine, propofol, monoamine oxidase inhibitors (MAOIs), atropine C linical Impact: These drugs augment the pressor effect of ephedrine. (एफेड्रिन लेबल, दवाओं के इंटरैक्शन)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (मिथाइलीन ब्लू लेबल, चेतावनियां और सावधानियां)

Examples: Nonsteroidal anti-inflammatory agents and other highly protein-boind drugs, salicylcates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, beta-adrenergic blocking agents; potentially with ciprofloxacin, micronazole. (ग्लिबेनक्लामाइड और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (मिथाइलीन ब्लू लेबल, चेतावनियां और सावधानियां)

Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. (टर्बिनाफिन लेबल, दवाओं के इंटरैक्शन)

It is theoretically possible, therefore, that the combination of Tolcapone tablets and a non-selective MAO inhibitor (e.g., phenelzine and tranylcypromine) would result in inhibition of the majority of the pathways responsible for normal catecholamine metabolism. (टोलकैपोन लेबल, चेतावनियां)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (मिथाइलीन ब्लू लेबल, चेतावनियां और सावधानियां)

Drug Interactions Since the chemical structure of difenoxin hydrochloride is similar to meperidine hydrochloride, the concurrent use of MOTOFEN ® with monoamine oxidase inhibitors may, in theory, precipitate a hypertensive crisis. (डाइफेनॉक्सिन और एट्रोपिन लेबल, दवाओं के इंटरैक्शन)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (मिथाइलीन ब्लू लेबल, चेतावनियां और सावधानियां)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (मिथाइलीन ब्लू लेबल, चेतावनियां और सावधानियां)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (मिथाइलीन ब्लू लेबल, चेतावनियां और सावधानियां)

Antidepressants: The hypotensive effect of MAO inhibitors or tricyclic antidepressants may be exacerbated when administered with beta-blockers. (प्रोप्रानोलोल लेबल, दवाओं के इंटरैक्शन)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (मिथाइलीन ब्लू लेबल, चेतावनियां और सावधानियां)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (मिथाइलीन ब्लू लेबल, चेतावनियां और सावधानियां)

Examples: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (रेपाग्लिनाइड लेबल, दवाओं के इंटरैक्शन)

A more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. (रोपिवाकेन लेबल, चेतावनियां और सावधानियां)

A more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. (लिडोकेन और प्रिलोकेन लेबल, चेतावनियां और सावधानियां)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (मिथाइलीन ब्लू लेबल, चेतावनियां और सावधानियां)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (मिथाइलीन ब्लू लेबल, चेतावनियां और सावधानियां)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (मिथाइलीन ब्लू लेबल, चेतावनियां और सावधानियां)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (मिथाइलीन ब्लू लेबल, चेतावनियां और सावधानियां)